Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.49 |
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741016 | 0.89 | PDE5A (0.58) | TERTPDE5ADRD2DRD3CA2 | |
| SCHEMBL8055436 | 0.86 | PDE5A (0.56) | TERTPDE5ADRD2DRD3CA2 | |
| SCHEMBL5739554 | 0.84 | TERT (0.50) | TERTPDE5A | |
| SCHEMBL4900976 | 0.82 | TERT (0.50) | TERTPDE5A | |
| SCHEMBL8065352 | 0.82 | PDE5A (0.52) | TERTPDE5ADRD2DRD3CA2 | |
| SCHEMBL7006683 | 0.82 | TERT (0.58) | TERTPDE5ALMNA | |
| SCHEMBL1705329 | 0.81 | TERT (0.61) | TERTPDE5AMAPTLMNA | |
| SCHEMBL13662766 | 0.81 | PDE5A (0.42) | TERTPDE5ADRD2DRD3CA2 | |
| SCHEMBL6284529 | 0.81 | TERT (0.53) | TERTPTGS1LMNA | |
| SCHEMBL8055635 | 0.80 | PDE5A (0.51) | TERTPDE5ADRD2DRD3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796286-B2 | Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative | MEZZION PHARMA CO., LTD. (KR) | 2014-08-05 | — | — | US | disclosed |
| EP-2167093-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | DONG A PHARM CO LTD (KR) | 2012-04-18 | — | — | EP | disclosed |
| EP-1888074-B1 | AGENT FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVE | DONG A PHARM CO LTD (KR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100173915-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2010-07-08 | — | — | US | disclosed |
| EP-2167093-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | Dong-A Pharmaceutical Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153282-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2008-12-18 | — | — | WO | disclosed |
| US-20080207646-A1 | Prevent collagen synthesis in liver cells; increase blood flow through portal vein; cirrhosis; long half-life | DONG-A PHARMACEUTICAL CO. LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | disclosed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207646-A1 | Prevent collagen synthesis in liver cells; increase blood flow through portal vein; cirrhosis; long half-life | COL1A1, COL14A1, COL2A1 | TERT 947/4885PDE5A 115/4885DRD2 3924/4885 |
| US-20100173915-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | PDE3B, PDE5A, PDE3A | TERT 1512/4885PDE5A 2/4885DRD2 4637/4885 |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | PDE3B, PDE8B, PDE5A | TERT 4593/4885PDE5A 3/4885DRD2 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.